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OBJECTIVE: A cost-effectiveness analysis was conducted
to compare the long-term clinical and economic benefits of
nateglinide, a new oral antidiabetic drug (OAD), plus met-
formin with metformin plus other OAD and with met-
formin alone in patients with type 2 diabetes whose glyce-
mia is not controlled with metformin monotherapy.
METHODS: The health status of a cohort of 10,000 type
2 diabetic patients at risk of developing microvascular
and macrovascular complications was simulated by a
Markov model, tracking patient evolution over 30 years
in one year periods. The risk of microvascular complica-
tions was based on published longitudinal studies. A
Weibull model predicted the incidence of macrovascular
complications depending on the level of glycemic control
(measured both in terms of HbA1c level and postprandial
glucose) and other patient characteristics. Costs of com-
plications were assessed as event costs covering the acute
and first-year management of the complication and state
costs, which occur in years after the event. The primary
outcome measure was the cost per Life Year Saved (LYS).
The analysis was conducted from a health-care-payer
perspective. Costs were discounted by 5% per year.
RESULTS: Type 2 diabetic patients taking nateglinide
plus metformin would live from 0.11 to 0.39 years more
than patients taking metformin plus OAD or metformin
alone. The total costs over the entire time horizon ranged
from 18,020 Euros for metformin alone to 20,694 Euros
for metformin plus nateglinide. The resulting cost-effec-
tiveness ratios (from 6,234 to 11,360 Euros per LYS)
with nateglinide are well within what is considered as
cost-effective care. In the sensitivity analysis, the impact
of the observed variation was moderate or in favour of
nateglinide plus metformin.
CONCLUSION: Nateglinide in combination with met-
formin is likely to be a cost-effective investment in type 2
diabetic patients inadequately controlled with metformin
alone.
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OBJECTIVE: To assess the cost-effectiveness of pioglita-
zone (PIO) in combination therapy versus usual care for
patients with type2 diabetes in Sweden.
METHODS: A published, validated model for type 1 dia-
betes mellitus developed by the Institute of Medical In-
formatics and Biostatistics was adapted to simulate long-
term (until death) management, health outcomes, resource
utilisation and treatment costs of patients with type2 dia-
betes. The model accounts for most complications occur-
ring in diabetes patients: nephropathy, retinopathy, acute
myocardial infarction, angina pectoris, stroke and ampu-
tation. The analysis was done from third-party-payer per-
spective and costs figured relative to the year 2000. A 3%
discount rate was applied to costs and outcomes and sen-
sitivity analysis was performed to test the results.
RESULTS: PIO in combination with metformin (MF)
was associated with longer life expectancy (15.6 years)
than sulphonylureas (SU)/MF (14.9) or rosiglitazone
(RSG) 8 mg/MF (15.5). The same applied for PIO 15 mg/SU
(15.5 years) with a greater life expectancy than MF/SU
(15.0) and RSG 4 mg/SU (15.3). Furthermore, PIO 30
mg/MF, PIO 30 mg/SU, PIO 15 mg/SU were associated
with the lowest number of serious complications. For ev-
ery 33 patients treated with PIO 30 mg/MF instead of
SU/MF, one death was avoided. The higher expense of
the PIO combination was offset in some, but not all sce-
narios, by a reduction in incidence of complications. The
incremental undiscounted cost per life year gained of PIO
30 mg/MF relative to SU/MF and RSG 8 mg/MF was re-
spectively 86,440 Sweden Kronor (SEK) and 123,313
SEK. After discounting both costs and life years at 3%,
the above becomes 146,196 SEK and 148,561 SEK, re-
spectively. Finally, after discounting, PIO 15 mg/SU ver-
sus MF/SU or RSG 4 mg/SU was associated with an in-
cremental cost per life year gained of 123,029 SEK and
42,401 SEK, respectively.
CONCLUSION: This model suggests that combined
treatments with pioglitazone improve survival and reduce
complications in patients with type2 diabetes and repre-
sent a cost-effective choice in Sweden when judged
against other therapeutic interventions. Nonetheless, the
results of modelling exercises such as this should be con-
firmed by long-term observational studies.
PDG7
THE LIFETIME DIRECT MEDICAL COSTS OF 
MANAGING DIABETES AND ITS 
COMPLICATIONS IN FRANCE
Grueger J1, O’Brien JA2, Caro JJ2, Brun C3, Everhard F1
1Novartis Pharmaceuticals AG, Basel, Switzerland; 2Caro 
Research Institute, Concord, MA, USA; 3Novartis Pharma,
Rueil Malmaison, France
OBJECTIVES: Several studies have assessed the cost of
micro- and macrovascular complications of diabetes. The
objective of this study was to examine the components of
the lifetime costs of diabetes in France.
